Applied DNA Sciences (APDN) stock fumbled in the after-market as in its Q4 financial report announced, the company reported a loss and missed revenue estimates.
The company lost $0.82 per share in its most recent quarter, compared with a $0.59 per share in the previous quarter. This compares to a loss of $1.44 per share last year, adjusted for non-recurring items.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
- Are You Looking for Dividend Paying Stocks? Here are the Best Buys in 2021
- Two Promising Pet Stocks for Investment as we Head 2021
The last quarter report represents an earnings surprise of -38.98%. A quarter ago, this DNA-based security technology company was expected to post a loss of $0.62 per share – however, it recorded a loss of $0.72, a surprise of -16.13%.
It hasn’t been able to surpass consensus EPS estimates over the last four quarters.
For the quarter ended September 2020, Applied DNA Sciences posted $0.31 million revenues, missing the Zacks Consensus Estimate by 55.14%. Revenues last year were $1.70 million. Over the last four quarters, the company has failed to surpass consensus revenue estimates.
Future earnings projections and management’s commentary during the earnings call will largely determine whether the stock’s immediate positive price movement can be sustained.
The shares of Applied DNA Sciences (APDN) have gained about 39.6% since the beginning of this year compared with the S&P 500’s gain of 14.6%.